China Journal of Leprosy and Skin Diseases ›› 2022, Vol. 38 ›› Issue (10): 741-746.doi: 10.12144/zgmfskin202210741

• Reviews • Previous Articles     Next Articles

Research progress in treatment of epidermolysis bullosa simplex

WANG Hua1, TANG Jiajian2, SHEN Ling1, SONG Yan1   

  1. 1 Guangzhou Link Health Pharma Co. Ltd, Guangzhou 510663,China;2 School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084,China
  • Online:2022-10-15 Published:2022-08-23

Abstract: Epidermolysis bullosa simplex is a rare genodermatosis. The current treatment focused on symptom-relieved therapies, including anti-inflammation, antipruritic and antiperspirant, and other treatments including mesenchymal stem cell, implantation of pluripotent stem cells and transcription activator-like effector nuclease, CRISPER/Cas9. The update of the treatments of epidermolysis bullosa is reviewed in this paper.

Key words: epidermolysis bullosa simplex, genodermatosis, keratin, Oleogel-S10, Diacerein